Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 12/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.53 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5474449 | 0.87 | JAK3 (0.51) | CYP1A2CYP3A4CYP2C19CLK4HSD17B10 | |
| SCHEMBL5477078 | 0.85 | ABL1 (0.48) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL5477111 | 0.81 | JAK3 (0.53) | CLK4MAPTSMN1; SMN2LMNAPOLB | |
| SCHEMBL13762188 | 0.81 | ALDH1A1 (0.69) | CYP1A2CYP3A4CYP2C19PLK1ALDH1A1 | |
| SCHEMBL5483168 | 0.80 | POLB (0.48) | CYP1A2CYP2C19CLK4KDM4EMAPT | |
| SCHEMBL5479302 | 0.80 | MEN1 (0.56) | CYP1A2CYP3A4CYP2C19CLK4HSD17B10 | |
| SCHEMBL18466143 | 0.79 | L3MBTL1 (0.53) | CYP1A2CYP3A4CYP2C19CLK4HSD17B10 | |
| SCHEMBL5478136 | 0.79 | KCNH2 (0.49) | CYP1A2CYP3A4CYP2C19HSD17B10ALDH1A1 | |
| SCHEMBL5473957 | 0.78 | MEN1 (0.62) | CYP1A2CYP3A4CYP2C19CLK4HSD17B10 | |
| SCHEMBL13757427 | 0.77 | LMNA (0.54) | CYP1A2CYP3A4CYP2C19CLK4PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161637-A1 | Substituted pyridin-2-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-07-12 | — | — | US | claimed |
| EP-1648877-A1 | SUBSTITUTED PYRIDIN-2-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005009980-A1 | SUBSTITUTED PYRIDIN-2-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| US-20070161637-A1 | Substituted pyridin-2-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161637-A1 | Substituted pyridin-2-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161637-A1 | Substituted pyridin-2-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161637-A1 | Substituted pyridin-2-ylamine analogues | PIGS, GPR35, GPR174 | CYP1A2 641/4885CYP3A4 1248/4885CYP2C19 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.